Programmed death-1 & its ligands: Promising targets for cancer immunotherapy

Rajeev Kumar Shrimali, John Edward Janik, Rasha Abu-Eid, Mikayel Mkrtichyan, Samir N. Khleif

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

Original languageEnglish (US)
Pages (from-to)777-792
Number of pages16
JournalImmunotherapy
Volume7
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

Immunotherapy
Ligands
Tumor Escape
Neoplasms
Immune Tolerance
Antibodies
Viral Tumor Antigens
Standard of Care
Melanoma
Therapeutics
T-Lymphocytes
Research
ipilimumab
pembrolizumab
nivolumab

Keywords

  • PD-1 receptor
  • PD-L1
  • PD-ligands
  • combination cancer immunotherapy
  • immune escape
  • immune inhibitory pathway

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Shrimali, R. K., Janik, J. E., Abu-Eid, R., Mkrtichyan, M., & Khleif, S. N. (2015). Programmed death-1 & its ligands: Promising targets for cancer immunotherapy. Immunotherapy, 7(7), 777-792. https://doi.org/10.2217/imt.15.49

Programmed death-1 & its ligands : Promising targets for cancer immunotherapy. / Shrimali, Rajeev Kumar; Janik, John Edward; Abu-Eid, Rasha; Mkrtichyan, Mikayel; Khleif, Samir N.

In: Immunotherapy, Vol. 7, No. 7, 01.01.2015, p. 777-792.

Research output: Contribution to journalReview article

Shrimali, RK, Janik, JE, Abu-Eid, R, Mkrtichyan, M & Khleif, SN 2015, 'Programmed death-1 & its ligands: Promising targets for cancer immunotherapy', Immunotherapy, vol. 7, no. 7, pp. 777-792. https://doi.org/10.2217/imt.15.49
Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: Promising targets for cancer immunotherapy. Immunotherapy. 2015 Jan 1;7(7):777-792. https://doi.org/10.2217/imt.15.49
Shrimali, Rajeev Kumar ; Janik, John Edward ; Abu-Eid, Rasha ; Mkrtichyan, Mikayel ; Khleif, Samir N. / Programmed death-1 & its ligands : Promising targets for cancer immunotherapy. In: Immunotherapy. 2015 ; Vol. 7, No. 7. pp. 777-792.
@article{c8e7703d59f3427f9782da1a426cfdbf,
title = "Programmed death-1 & its ligands: Promising targets for cancer immunotherapy",
abstract = "Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.",
keywords = "PD-1 receptor, PD-L1, PD-ligands, combination cancer immunotherapy, immune escape, immune inhibitory pathway",
author = "Shrimali, {Rajeev Kumar} and Janik, {John Edward} and Rasha Abu-Eid and Mikayel Mkrtichyan and Khleif, {Samir N.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/imt.15.49",
language = "English (US)",
volume = "7",
pages = "777--792",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Programmed death-1 & its ligands

T2 - Promising targets for cancer immunotherapy

AU - Shrimali, Rajeev Kumar

AU - Janik, John Edward

AU - Abu-Eid, Rasha

AU - Mkrtichyan, Mikayel

AU - Khleif, Samir N.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

AB - Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

KW - PD-1 receptor

KW - PD-L1

KW - PD-ligands

KW - combination cancer immunotherapy

KW - immune escape

KW - immune inhibitory pathway

UR - http://www.scopus.com/inward/record.url?scp=84942121935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942121935&partnerID=8YFLogxK

U2 - 10.2217/imt.15.49

DO - 10.2217/imt.15.49

M3 - Review article

C2 - 26250412

AN - SCOPUS:84942121935

VL - 7

SP - 777

EP - 792

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 7

ER -